La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zynex Bilan de santé

Santé financière contrôle des critères 4/6

Zynex possède un total de capitaux propres de $32.8M et une dette totale de $58.1M, ce qui porte son ratio d'endettement à 177%. Son actif total et son passif total sont $121.9M et de $89.1M. L'EBIT de Zynex est $10.5M ce qui fait que son ratio de couverture des intérêts 5.7. Elle dispose de liquidités et de placements à court terme de $30.9M.

Informations clés

177.0%

Ratio d'endettement

US$58.08m

Dette

Ratio de couverture des intérêts	5.7x
Argent liquide	US$30.90m
Fonds propres	US$32.82m
Total du passif	US$89.10m
Total des actifs	US$121.92m

Mises à jour récentes de la santé financière

Recent updates

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Jul 31

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Jan 24

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Aug 03

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Mar 30

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Jan 23

Short Squeeze Candidate With Low PEG Ratio: Zynex

Oct 05

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ZYXI ( $74.1M ) dépassent ses passifs à court terme ( $18.2M ).

Passif à long terme: Les actifs à court terme de ZYXI ( $74.1M ) dépassent ses passifs à long terme ( $70.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ZYXI ( 82.8% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de ZYXI est passé de 0% à 177% au cours des 5 dernières années.

Couverture de la dette: La dette de ZYXI est bien couverte par le flux de trésorerie opérationnel ( 31.5% ).

Couverture des intérêts: Les paiements d'intérêts de ZYXI sur sa dette sont bien couverts par l'EBIT ( 5.7 x couverture).

Zynex Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Recent updates

Zynex, Inc. Obtains FDA Clearance for New Pain Management Device

Chief Operating Officer recently sold US$199k worth of stock

Investor sentiment deteriorates as stock falls 18%

Chief Financial Officer recently sold US$124k worth of stock

Consensus revenue estimates decrease by 11%

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Price target decreased by 17% to US$17.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Zynex, Inc.(NasdaqGS:ZYXI) dropped from Russell 2000 Growth-Defensive Index

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Zynex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Zynex, Inc. Reiterates Revenue Guidance Full Year 2022